Cargando…
Reflecting on the advancements of HFrEF therapies over the last two decades and predicting what is yet to come
What was once considered a topic best avoided, managing heart failure with reduced ejection fraction (HFrEF) has become the focus of many drug and device therapies. While the four pillars of guideline-directed medical therapies have successfully reduced heart failure hospitalizations, and some have...
Autores principales: | Piña, Ileana L, Gibson, Gregory T, Zieroth, Shelley, Kataria, Rachna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9762889/ https://www.ncbi.nlm.nih.gov/pubmed/36545229 http://dx.doi.org/10.1093/eurheartjsupp/suac112 |
Ejemplares similares
-
Aiming at harmony. Comparing and contrasting International HFrEF Guidelines
por: Tomasoni, Daniela, et al.
Publicado: (2022) -
Getting ahead of the game: in-hospital initiation of HFrEF therapies
por: Biegus, Jan, et al.
Publicado: (2022) -
The four pillars of HFrEF therapy: is it time to treat heart failure regardless of ejection fraction?
por: Docherty, Kieran F, et al.
Publicado: (2022) -
Time for change
por: Zieroth, Shelley, et al.
Publicado: (2022) -
Dear colleagues: enough with the men-only author panels
por: Van Spall, Harriette G C, et al.
Publicado: (2022)